Published : 27 Mar 2025

---

We are pleased to announce a new client win. The client is a California based company with Phase 3 stage small molecule eye drop to treat pre-surgical cataract (typically patients under 72 years of age).

 

Aagami has been assigned to find and establish Co-development/Licensing partnership for their assets and technologies:

1.        Phase 3 ready eye drops to improve vision in early-to-moderate cataracts. Finished positive end-of-phase 2 FDA meeting. Preparing to start Phase 3 clinical trials.

2.        Commercially available toothpaste generating profitable revenue stream. EU CE Mark approved for treatment and prevention of periodontitis. Already expanded sales to Japan and Middle East.

3.        Proof of concept international study completed for reducing edema in chronic venous insufficiency (CVI) patients. Ready to initiate Phase 1/2 trial for CVI treatment using a topical application.

In case you would like to know more about any of these, please contact us.